VerityRankVerityRank
Back to Rankings
Abbott Laboratories
Manufacturer VerifiedUnited States

Abbott Laboratories

CGM

Abbott Laboratories is the global leader in continuous glucose monitoring (CGM) technology through its revolutionary FreeStyle Libre system, headquartered in Abbott Park, Illinois, USA since 1888. With annual revenue of $44.3 billion in 2025, the company operates 100+ manufacturing and R&D facilities worldwide, employing 114,000+ people across 160+ countries. Abbott's Diabetes Care division alone generated $7.6 billion in 2025, driven by the FreeStyle Libre CGM franchise — the dominant platform in home-based glucose monitoring. The company's landmark $23 billion acquisition of Exact Sciences in 2025 signals its strategic expansion into at-home cancer screening and precision oncology diagnostics.

Strengths: Unrivaled CGM technology with FreeStyle Libre achieving near-monopoly status in home diabetes monitoring; massive R&D investment exceeding $2.5 billion annually across diagnostics, medical devices, and nutrition; vertically integrated global manufacturing network spanning 100+ facilities worldwide; diversified revenue base reducing single-market dependency; and transformative $23 billion Exact Sciences acquisition positioning Abbott as the future leader in home-based cancer screening and diagnostics.

Weaknesses: Heavy dependence on the Diabetes Care segment for growth momentum; significant execution and integration risks associated with the $23 billion Exact Sciences acquisition; and intensifying competition from Dexcom's next-generation G7 CGM system in the rapidly expanding glucose monitoring market.
Read More ▼
United StatesEst. 1888114,000$44.33B (FY2025)~100 manufacturing and R&D facilities globallyNYSE:ABTScore 91
Last Updated: September 2026·By VerityRank Research Team·Methodology

Business Nature

Abbott Laboratories operates a vertically integrated, research-driven global manufacturing model. The company maintains complete control over its supply chain from raw material sourcing to final device assembly, with 100+ facilities spanning North America, Europe, Asia, and Latin America. Abbott's CGM sensor production exemplifies its advanced manufacturing capabilities, with annual output capacity reaching hundreds of millions of units through highly automated fabrication processes. The company balances proprietary in-house manufacturing for its core medical device products with strategic technology acquisitions to expand its portfolio into adjacent diagnostic and therapeutic categories.

Core Business Areas

Core Laboratory Diagnostics – Core Business
• ARCHITECT and Alinity immunoassay systems
• Clinical chemistry analyzers and integrated automation
• Hematology CELL-DYN, Alinity h-series

Rapid & Molecular Diagnostics – Core Business
• POC infectious disease testing BinaxNOW, ID NOW
• Molecular diagnostics platforms

Point-of-Care & Consumer Diagnostics – Core Business
• FreeStyle Libre continuous glucose monitoring
• i-STAT blood gas and critical care testing

Medical Devices & Monitoring – Core Business
• Structural heart, rhythm management, and neuromodulation devices
• Diabetes care systems beyond glucose monitoring

Industry Rankings

Corporate Report

Abbott Laboratories (NYSE: ABT), headquartered in Chicago, Illinois, is a diversified healthcare company operating in 160+ countries with approximately 114,000 employees. The company maintains a comprehensive business model encompassing research, development, manufacturing, and distribution across multiple healthcare sectors. Abbott holds a brand leadership score of 91/100 in the global medical nutrition industry.

Core Business

Abbott operates through four primary business segments that span the full spectrum of healthcare needs. The Medical Devices segment represents the largest portion of revenue at 40%, generating $17.2 billion and including innovative cardiovascular, diabetes care, and neuromodulation technologies. The Diagnostics segment contributes 25% of total revenue at $10.75 billion, providing comprehensive laboratory and point-of-care testing solutions globally.

Within the Nutrition segment, which generated $8.17 billion in revenue, Abbott maintains dominant market positions through its portfolio of trusted brands. Similac leads the infant nutrition category at $4.5 billion, representing 55% of nutrition revenue, while Ensure anchors the adult nutrition business at $2.86 billion. The company also serves specialized nutritional needs through Glucerna and PediaSure, addressing specific medical nutrition requirements across patient populations. The Pharmaceuticals segment rounds out the portfolio at $6.88 billion, focusing on key therapeutic areas.

In 2024, Abbott achieved total revenues of $43 billion representing 4.2% year-over-year growth, with operating income reaching $8.5 billion and net income totaling $6.5 billion. The company invested $2.5 billion in research and development, a 7.5% increase, demonstrating its commitment to advancing healthcare innovation.

Global Presence

Abbott's global footprint extends across 160+ countries with approximately 114,000 employees supporting operations worldwide. The company's manufacturing infrastructure encompasses more than 30 facilities with an annual production capacity exceeding 500,000 tons, enabling reliable supply chain operations across diverse markets. Abbott maintains 12 research and development centers staffed by over 5,000 researchers who drive continuous innovation across all business segments.

Strategic expansion efforts are concentrated in high-growth emerging markets, with China delivering 8.2% growth, the Middle East achieving 9.8% expansion, and Africa realizing 12.5% growth rates. The company's extensive distribution network reaches medical professionals and consumers across both developed and developing economies, supporting sustainable long-term growth trajectories in these key regions.

Key Strengths

Abbott's leadership position stems from its pharmaceutical-grade quality standards, achieving a 99.8% global audit pass rate and maintaining the industry's lowest product recall rate. The company conducts over 300 clinical studies annually, generating robust evidence supporting product efficacy and safety across all categories. A comprehensive multi-brand portfolio covers the full consumer lifecycle from infant to adult nutrition, supported by extensive medical professional distribution networks that build sustainable competitive advantages.

The company's commitment to sustainability further strengthens its market position, having exceeded carbon reduction targets by 30% while achieving 70% renewable energy usage across operations. With ongoing investment in innovation and geographic expansion, Abbott is positioned to maintain its global healthcare leadership while addressing evolving consumer and clinical needs worldwide.

VerityRank Score

VerityRank Score of 91/100

VerityRank Score

91/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Zurich, Zurich Canton, Switzerland

Founded

1888

Employees

114,000

Factories

~100 manufacturing and R&D facilities globally

Listing

NYSE: ABT

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE:ABT , Data Sources & Methodology

Abbott Official Website
Abbott Laboratories - Wikipedia
Abbott 2025 Annual Report
Abbott Q1 2026 Earnings